GAITHERSBURG, Md., Nov. 12 /PRNewswire-USNewswire/ -- MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, announces that it will be hosting a live discussion with industry experts on the challenges in developing cell-based screening assays for drug discovery. The discussion is open to the industry and will be held by webinar on Thursday, November 13th from 2:00-3:00EST.
One of the respected industry experts leading this live discussion is Dr. John Reardon, formerly Senior Vice President of Discovery Research Biology at GSK and now Executive Vice President and Chief Scientific Officer at Integrated Oncology Solutions Inc (IOS) in North Carolina. Dr. Reardon will review the complexities of cell transfection technologies and challenge the webinar participants to consider the possibilities of creating more relevant assays if it were possible to transfect any molecule into any cell at any scale, while maintaining biological integrity and the high quality standards. His discussion will offer compelling arguments as to how the MaxCyte(R) STX System can reduce bottlenecks and improve the productivity of drug discovery groups.
Dr. James Brady, Director Technical Applications, will lead the webinar participants through a technical presentation of the MaxCyte(R) STX System. Dr. Brady will demonstrate how the MaxCyte STX technology enables the large scale transfection of primary cells, cell lines, and stem cells with multiple loading agents at the same time, resulting in more relevant screening systems.
According to MaxCyte CEO Doug Doerfler, "We are delighted to have the
enthusiastic validation for our technology from such a renowned industry
expert as Dr. Reardon. The MaxCyte STX is being viewed by the
pharmaceutical industry as an enabling technology for cell modification for
both research and larger scale cell-based applications in drug discovery.
The MaxCyte STX can produce a large number of transfected cells in minute
|SOURCE MaxCyte, Inc.|
Copyright©2008 PR Newswire.
All rights reserved